Coya Therapeutics (COYA) Stock Overview
A clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
COYA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Coya Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.00 |
| 52 Week High | US$8.29 |
| 52 Week Low | US$4.65 |
| Beta | 0.20 |
| 1 Month Change | -1.64% |
| 3 Month Change | -6.69% |
| 1 Year Change | -12.41% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 31.29% |
Recent News & Updates
Recent updates
Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?
Sep 16
We Think Coya Therapeutics (NASDAQ:COYA) Can Afford To Drive Business Growth
Apr 04Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth
Oct 29Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts
Oct 13Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans
Mar 26Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal
Feb 13Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position
Jan 13We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully
Sep 06Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
May 17Shareholder Returns
| COYA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.3% | 0.8% | -0.9% |
| 1Y | -12.4% | 2.6% | 20.1% |
Return vs Industry: COYA underperformed the US Biotechs industry which returned 4% over the past year.
Return vs Market: COYA underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| COYA volatility | |
|---|---|
| COYA Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COYA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: COYA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 8 | Arun Swaminathan | coyatherapeutics.com |
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer’s disease (AD), and Parkinson’s disease.
Coya Therapeutics, Inc. Fundamentals Summary
| COYA fundamental statistics | |
|---|---|
| Market cap | US$105.70m |
| Earnings (TTM) | -US$20.34m |
| Revenue (TTM) | US$423.45k |
Is COYA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COYA income statement (TTM) | |
|---|---|
| Revenue | US$423.45k |
| Cost of Revenue | US$13.04m |
| Gross Profit | -US$12.62m |
| Other Expenses | US$7.72m |
| Earnings | -US$20.34m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | -2,979.10% |
| Net Profit Margin | -4,803.12% |
| Debt/Equity Ratio | 0% |
How did COYA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 08:58 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Coya Therapeutics, Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Shrader | BTIG |
| Keay Nakae | Chardan Capital Markets, LLC |
| Jason Kolbert | D. Boral Capital LLC. |